AWAKN is integrating psychedelic medicine into mainstream mental healthcare in order to address a US$700bn annual problem across the UK and Europe. We work across three divisions - Research, Clinics and Training.  Our scientific team is led by Prof David Nutt and Dr Ben Sessa. 

Get in touch for more information:

Investor Relations - investors@awaknlifesciences.com

Media Inquiries - media@awaknlifesciences.com